Want to see HK:2162 full AI Analyst Report?
2162 Stock Chart & Stats
HK$62.80
HK$0.80(2.86%)
At close: 4:00 PM EST
HK$62.80
HK$0.80(2.86%)
Day’s Range― - ―
52-Week RangeHK$44.66 - HK$89.75
Previous CloseN/A
Volume918.50K
Average Volume (3M)1.75M
Market Cap
HK$20.52B
Enterprise ValueHK$14.44K
Total Cash (Recent Filing)HK$1.96B
Total Debt (Recent Filing)HK$788.88M
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Sep 01, 2026EPS Estimate
5.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.76
Shares Outstanding298,735,570
10 Day Avg. Volume1,976,819
30 Day Avg. Volume1,752,076
Financial Highlights & Ratios
PEG Ratio4.62
Price to Book (P/B)4.74
Price to Sales (P/S)18.85
P/FCF Ratio-12.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$108.46Price Target Upside72.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)2.03
Revenue Forecast (FY)HK$2.26B
Bulls Say, Bears Say
Bulls Say
Therapeutic Focus & PipelineA concentrated R&D focus in oncology and immunology creates durable structural opportunity: large unmet medical needs, premium pricing potential, and sustained partner interest. A pipeline spanning early research to clinical development increases long‑term product optionality and out‑licensing value.
Revenue Scaling Track RecordSubstantial top‑line growth from a small base demonstrates the company’s ability to commercialize or monetize assets and scale operations. That multi‑year scaling provides a foundation for future revenue recovery and validates the commercial/partnering model beyond one‑off growth spurts.
Balance Sheet CushionRelatively strong equity and low leverage give the company financial flexibility to fund R&D, complete clinical programs, or pursue partnerships without immediate solvency pressure. Asset growth suggests capacity to invest further, which supports multi‑quarter operational continuity.
Bears Say
Negative Cash GenerationSustained negative operating and free cash flow indicates heavy cash burn and reliance on external financing or partner milestones. Over a 2–6 month horizon this constrains discretionary investment, increases funding risk if markets tighten, and can force dilutive measures or deal concessions.
Large Operating LossesDeep, persistent operating deficits mean a long path to profitability and pressure on returns. Even with strong gross margins, SG&A and R&D scale create negative operating leverage, raising the probability of continued external funding needs and limiting free cash available for growth initiatives.
Recent Revenue ContractionA ~20% revenue decline after prior scaling signals execution or market access issues that could persist. Revenue volatility undermines visibility for R&D prioritization and partner planning, increasing the risk that sustained top‑line weakness will prolong cash burn and strategic dilution.
Keymed Biosciences, Inc. News
2162 FAQ
What was Keymed Biosciences, Inc.’s price range in the past 12 months?
Keymed Biosciences, Inc. lowest stock price was HK$44.66 and its highest was HK$89.75 in the past 12 months.
What is Keymed Biosciences, Inc.’s market cap?
Keymed Biosciences, Inc.’s market cap is HK$20.52B.
When is Keymed Biosciences, Inc.’s upcoming earnings report date?
Keymed Biosciences, Inc.’s upcoming earnings report date is Sep 01, 2026 which is in 25 days.
How were Keymed Biosciences, Inc.’s earnings last quarter?
Keymed Biosciences, Inc. released its earnings results on Mar 26, 2026. The company reported -HK$1.859 earnings per share for the quarter, missing the consensus estimate of -HK$1.517 by -HK$0.342.
Is Keymed Biosciences, Inc. overvalued?
According to Wall Street analysts Keymed Biosciences, Inc.’s price is currently Undervalued.
Does Keymed Biosciences, Inc. pay dividends?
Keymed Biosciences, Inc. does not currently pay dividends.
What is Keymed Biosciences, Inc.’s EPS estimate?
Keymed Biosciences, Inc.’s EPS estimate is 5.33.
How many shares outstanding does Keymed Biosciences, Inc. have?
Keymed Biosciences, Inc. has 298,735,570 shares outstanding.
What happened to Keymed Biosciences, Inc.’s price movement after its last earnings report?
Keymed Biosciences, Inc. reported an EPS of -HK$1.859 in its last earnings report, missing expectations of -HK$1.517. Following the earnings report the stock price went up 0.174%.
Which hedge fund is a major shareholder of Keymed Biosciences, Inc.?
Currently, no hedge funds are holding shares in HK:2162
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Keymed Biosciences, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
69.01%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
17.19%
Trailing 12-Months
Company Description
Keymed Biosciences, Inc.
Keymed Biosciences Inc., a biotechnology firm founded in 2016 in Chengdu, China (formerly known as 2Health Biosciences, Inc.), specializes in the research and development of innovative biological treatments, primarily targeting autoimmune and oncology diseases. A cornerstone of their pipeline is CM310, their lead product candidate, which is currently being developed for the management of moderate to severe atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic obstructive pulmonary disease (COPD). Complementing this, the company is also progressing CM326, a monoclonal antibody designed to inhibit thymic stromal lymphopoietin, for similar indications such as AD, CRSwNP, asthma, and COPD. In the realm of oncology, Keymed is developing CMG901 for solid tumors, particularly those affecting the stomach and gastroesophageal junction. Another significant candidate, CM313, is a humanized monoclonal antibody slated for the treatment of relapsed or refractory multiple myeloma, lymphoma, other blood cancers, and systemic lupus erythematosus. Their extensive portfolio further includes MIL95/CM312, a humanized monoclonal antibody targeting CD47; CM338, an antagonist antibody against mannose-binding lectin-associated serine protease-2; CM355, intended for relapsed or refractory non-Hodgkin's lymphoma; CM336, for multiple myeloma; CM350, for various solid tumors; and CM369, an anti-CC chemokine receptor 8 monoclonal antibody.
2162 Stock 12 Month Forecast
Average Price Target
HK$108.46
▲(72.71% Upside)
Technical Analysis
Zai Lab Ltd
―
Alphamab Oncology
―
InnoCare Pharma Ltd.
―
CStone Pharmaceuticals
―
Ascentage Pharma Group International
―